Surufatinib targets both the VEGF receptor and the CSF1R receptor, which is a unique mechanism of action.
In an interview with Pharmacy Times about her presentation at the North American Neuroendocrine Tumor Society (NANETS) 2021 neuroendocrine tumor (NET) Medical Symposium, Mei Ka Fong, PharmD, BCOP, said the potential FDA approval of surufatinib could be very important for patients.
Fong said surufatinib targets both the VEGF receptor and the CSF1R receptor, which is a unique mechanism of action.By targeting both receptors, surufatinib targets both the angiogenesis and the tumor tumor's immune evasion, which could make a significant difference in the treatment of NETs.
"exciting" - Google News
November 06, 2021 at 10:00PM
https://ift.tt/2ZYw0gu
Expert: Potential Surufatinib FDA Approval for Neuroendocrine Tumors Is "Really Exciting" - Pharmacy Times
"exciting" - Google News
https://ift.tt/2GLT7hy
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
Bagikan Berita Ini
0 Response to "Expert: Potential Surufatinib FDA Approval for Neuroendocrine Tumors Is "Really Exciting" - Pharmacy Times"
Post a Comment